c-KIT/PDGFRA mutations influence the prognosis of GIST patients, and those molecular biomarkers can provide guidance for adjuvant chemotherapy, resulting in a better prognosis for GIST patients. This evidence concerns the gene KIT and gastrointestinal stromal tumor.